References
- Pozzilli C, Schweikert B, Ecari U, et al.; BetaPlus Study Group . Supportive strategies to improve adherence to IFN beta-1b in multiple sclerosis—results of the BetaPlus observational cohort study. J Neurol Sci. 2011;307:120–126.
- Bayas A, Ouallet JC, Kallmann B, et al.; SMART study group. Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Expert Opin Drug Deliv. 2015 Aug; 12(8):1239–1250.
- Ziemssen T, Sylvester L, Rametta M, et al. Patient satisfaction with the new interferon Beta-1b autoinjector (BETACONNECT™). Neurol Ther. 2015 Dec;4(2):125–136.
- Limmroth V, Gerbershagen K. Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1a. Expert Opin Drug Deliv. 2014 Dec;11(12):1969–1978.
- Umasunthar T, Procktor A, Hodes M, et al. Patients’ ability to treat anaphylaxis using adrenaline autoinjectors: a randomized controlled trial. Allergy. 2015 Jul;70(7):855–863.
- Schulze-Koops H, Giacomelli R, Samborski W, et al. Factors influencing the patient evaluation of injection experience with the smartject autoinjector in rheumatoid arthritis. Clin Exp Rheumatol. 2015 Mar-Apr;33(2):201–208.
- Freundlich B, Kivitz A, Jaffe JS. Nearly pain-free self-administration of subcutaneous methotrexate with an autoinjector: results of a phase 2 clinical trial in patients with rheumatoid arthritis who have functional limitations. J Clin Rheumatol. 2014 Aug;20(5):256–260.
- Yadlapati S, Efthimiou P. Inadequate response or intolerability to oral methotrexate: is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics? Rheumatol Int. 2016 May;36(5):627–633.
- Pichlmeier U, Heuer KU. Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. Clin Exp Rheumatol. 2014 Jul-Aug;32(4):563–571.
- Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31(4):645–648.
- Paul C, Lacour JP, Tedremets L, et al.; JUNCTURE study group. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015 Jun; 29(6):1082–1090.
- Weiss RC, Bazalo GR, Thomson H, et al. Economic impact of a novel naloxone autoinjector on third-party payers. Manag Care. 2015 Feb;24(2):41–48.
- Available from: http://www.amgen.com/media/news-releases/2016/07/fda-approves-first-and-only-single-monthly-injection-for-a-pcsk9-inhibitor/
- Huskisson EC. Measurement of pain. Lancet. 1974;2(1):127–131.
- Simons FE, Lieberman PL, Read EJ Jr, et al. Hazards of unintentional injection of epinephrine from autoinjectors: a systematic review. Ann Allergy Asthma Immunol. 2009 Apr;102(4):282–287.
- Brown JC, Tuuri RE, Akhter S, et al. Lacerations and embedded needles caused by epinephrine autoinjector use in children. Ann Emerg Med. 2016 Mar;67(3):307–315.
- Guerlain S, Hugine A, Wang L. A comparison of 4 epinephrine autoinjector delivery systems: usability and patient preference. Ann Allergy Asthma Immunol. 2010 Feb;104(2):172–177.